Providing Access to the Latest Cancer Clinical Trials
Thanks to our affiliation with Duke Medicine, people with cancer have access to cutting-edge therapies available in clinical trials. Our clinical trials program is approved by the Cancer and Leukemia Group B, a national clinical research group sponsored by the National Cancer Institute. Our cancer center staff works closely with the Duke Oncology Network to choose appropriate trials. To date, many of our trials have focused on lung, breast, colon and prostate cancer.
Current breast cancer trials:
- Protocol E1Z11: Postmenopausal women who have breast cancer
that is ER/PR positive can enroll in a study to evaluate genetic predictors for
Aromatase Inhibitor Musculoskeletal Symptoms.
Protocol SCUSF 0806: HER2-positive breast cancer patients
can enroll in a study testing drugs that protect heart function during
Protocol NSABP B 47: Patients with early stage HER2-low
breast cancer can enroll in a study to see if adding Herceptin to standard
treatment reduces recurrence risk.
Protocol S1202: Patient currently taking aromatase inhibitor
and experiencing muscle or bone pain can enroll in a research study evaluating
the use of Cymbalta and the relief of joint pain.
Protocol S1207: Patients being treated for
high-risk breast cancer can enroll in a study that adds Afinitor to their
standard hormone therapy to determine if this will delay cancer’s spread or
Current colorectal cancer trials:
Current cancer control trials:
- Protocol S0820: Patients with the history of Stage 0, I, II
or III colon cancer who completed surgery during the previous 9 – 15 months can
enroll in a study evaluating whether the use of Eflornithine and Sulindac,
taken alone or in combination, will help decrease the risk of high-risk
adenomas or second primary colorectal cancer.
- Protocol A221301: Patients who will be starting chemotherapy may be
given Olanzapine (Zyrpexa) to the standard treatment to determine if it helps
to reduce nausea and vomiting associated with chemotherapy.
To learn more, call 843-522-7819.